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Objective: To evaluate the functional and anatomical response after the switch from 
bevacizumab to aflibercept in treatment-resistant wet age-related macular degeneration 
(wAMD) using the treat-and-extend regimen protocol.
Design: A retrospective single-center study.
Participants: The registry consisted of 576 patients with wAMD. Of these, a total of 41 eyes 
of 37 patients met the study inclusion criteria with a minimum of three prior bevacizumab 
injections and at least 1-year follow-up after the switch to aflibercept injections for the treat-
ment of wAMD.
Methods: Central retinal thickness (CRT) and best-corrected visual acuity (BCVA) were 
recorded before and after bevacizumab loading phase, before the switch to aflibercept, after 
aflibercept loading phase, and after the last injection or at the study end point at a minimum of 
1 year from the switch.
Results: At the switch to aflibercept injections, the mean CRT was 361.1±117.7 µm (mean±SD) 
and BCVA was 0.29±0.19 decimals. The switch to aflibercept resulted in mean CRT resolu-
tion by 59.9±80.2 µm after the loading phase and by 61.3±102.9 µm at the study end point. 
Anatomical response to aflibercept switch was found in 34 of 41 eyes (83%) after the loading 
phase, and in 32 of 41 eyes (78%) at the study end point. BCVA improvement was 0.08±0.13 
decimals in 26 of 41 eyes (63%) after the loading phase, and 0.04±0.17 decimals in 17 of 41 eyes 
(41%) at the study end point. The mean treatment interval of aflibercept was 8.0±2.2 weeks at 
the study end point.
Conclusion: Regardless of impressive anatomical outcomes of aflibercept switch, functional 
response was modest for most of the study eyes at long term.
Keywords: aflibercept, anti-VEGF, bevacizumab, treat-and-extend regimen protocol, wet 
age-related macular degeneration
Introduction
Age-related macular degeneration (AMD) is a common cause for irreversible visual 
impairment and blindness among the elderly.1,2 The wet age-related macular degenera-
tion (wAMD) usually leads to a rapid loss of vision and is characterized by intraretinal 
or subretinal fluid and hemorrhage.3 Vascular endothelial growth factor (VEGF) plays 
a major role in the pathogenesis of wAMD by promoting angiogenesis and vascular 
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permeability. Anti-VEGF agents given by intravitreal injec-
tions have become the standard of care in wAMD.4
The efficacy of anti-VEGF injections in the treatment of 
wAMD was first demonstrated with ranibizumab in two trials. 
Monthly treatment with ranibizumab was found to prevent 
vision loss and even improve visual acuity (VA) in some 
patients.5,6 Bevacizumab was found to have a similar efficacy 
and safety compared to ranibizumab, and is now widely used 
off-label as the first-line therapy in treating patients with 
wAMD.7,8 Aflibercept is a newer recombinant fusion protein. 
Compared with other anti-VEGF agents, aflibercept has a 
considerably greater binding affinity to VEGF and it also 
binds placental growth factor (PlGF).9 Treatment with afliber-
cept every 8 weeks has been shown to provide equal gain 
in VA compared to monthly treatment with ranibizumab.10 
A recent meta-analysis demonstrated positive anatomical 
results with aflibercept in patients resistant to previous treat-
ment with another anti-VEGF agent.11
The treatment protocols vary among different studies. 
A majority of earlier studies have used a fixed-interval treat-
ment protocol with monthly injections,5,6 or a pro re nata 
regimen, where injections are given only when signs of active 
disease are observed.7,8 Both protocols require monthly visits, 
which burdens both the patient and the healthcare system. 
In the treat-and-extend regimen (TER) protocol, the objective 
is to gradually extend the treatment and follow-up interval 
while trying to avoid relapses of the disease. Many studies 
have shown equal visual gain with fewer injections using the 
TER protocol compared with monthly injections.12–14
In this study, we present results on the efficacy of afliber-
cept using the TER protocol in patients with wAMD resistant 
to previous treatment with bevacizumab. We evaluated the 
functional and anatomical response by measuring VA and 
central retinal thickness (CRT) before and after the switch 
from bevacizumab to aflibercept.
Methods
study design
The study design was an institutional, retrospective, 
register-based, observational study. The study proto-
col was evaluated by the Institutional Review Board of 
Helsinki University Hospital. The study was approved by 
the Research Director and Chief Medical Officer of the 
Kymenlaakso Central Hospital and conducted according 
to the Declaration of Helsinki.
Patients were admitted for the management of wAMD 
to the Department of Ophthalmology, Kymenlaakso Central 
Hospital, Kotka, Finland. All eyes with wAMD included in 
the retrospective analysis had a minimum of three prior beva-
cizumab (Avastin®; Genentech, Inc., South San Francisco, 
CA, USA) injections (1.25 mg/0.05 mL), a minimum of 
three aflibercept (Eylea®; Bayer Leverkusen, Leverkusen, 
Germany) injections (2 mg/0.05 mL), a minimum of 1-year 
follow-up after the switch to aflibercept and were treatment-
naïve for aflibercept at the time of the switch. None of the 
eyes were treated with ranibizumab (Lucentis®; Novartis, 
Basel, Switzerland) at any time. The diagnosis of wAMD 
was carried out by a physician specialized in its diagnosis and 
treatment, and all cases were treated using the TER protocol 
regardless of the anti-VEGF agent.
Bevacizumab was the first-line anti-VEGF agent in 
the treatment of wAMD. The choice of therapies between 
different anti-VEGF agents (bevacizumab or aflibercept) 
was at the discretion of the treating physician. Outcome 
measures were CRT and best-corrected visual acuity (BCVA) 
at baseline before the first bevacizumab intravitreal injection, 
after the bevacizumab loading phase, before the switch to 
aflibercept, after the aflibercept loading phase, and at termi-
nation of the treatment and/or follow-up at least after 1 year 
from the switch. The proportion of the eyes responding to the 
conversion to aflibercept was recorded. The final treatment 
interval with aflibercept was also determined.
This study was conducted by monitoring the clinical prac-
tice. The study was approved by the Research Director and 
Chief Medical Officer of the Kymenlaakso Central Hospital. 
Confidentiality of the patient records was maintained while 
entering the clinical data to a computer-based standardized 
database for analysis.
Participant criteria
The source of patients comprised the Kymenlaakso Health 
Care District Population and as such was representative of the 
entire source population (n=174,000). The registry consisted 
of 576 patients with wAMD (ICD code: H35.31) who were 
given intravitreal injections (ICD code: CKD05) between 
January 1, 2011 and September 30, 2016. Follow-up of the 
patients was terminated on September 30, 2017. Of these, 
a total of 41 eyes of 37 patients met the study inclusion 
criteria which are as follow: 1) a minimum of three prior 
bevacizumab injections, 2) a minimum of three aflibercept 
injections after the switch, 3) treatment naïve for aflibercept 
at the time of the switch, 4) no ranibizumab treatment at any 
time, and 5) a minimum of 1 year follow-up after the switch 
to aflibercept.
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The treated eye was considered a nonresponder to the 
drug, when observing unchanged or increased CRT within 
three consecutive intravitreal injections with the shortest 
4-week treatment interval.
The baseline variables are presented in Table 1.
Clinical evaluation
The diagnosis of wAMD was carried out by a physician spe-
cialized in its diagnosis and treatment. Clinical examination 
included bilateral VA testing, biomicroscopy, tonometry, 
and examination of the fundus. Fluorescein angiography 
was performed when necessary. Initiation of anti-VEGF 
treatment was performed on the day of the diagnosis in most 
of the cases.
The CRT was recorded by spectral-domain optical coher-
ence tomography (OCT; Heidelberg Engineering GmbH, 
Heidelberg, Germany) by an experienced ophthalmic nurse. 
Follow-up 30-frame scans were performed with AutoRescan™ 
software, and the OCT analyses were compared to the pre-
vious ones (Heidelberg Eye Explorer Version 1.9.10.0 and 
HRA/SPECTRALIS® Viewing Module Version 6.0.9.0; 
Heidelberg Engineering GmbH).
The eligibility of the patient for treatment with afliber-
cept was estimated with the aid of guiding principles. These 
included no subretinal fibrosis, no geographic atrophy in 
the fovea, and a BCVA of 0.1 decimals or more in the 
treated eye. However, the treatment decision was always 
made case-by-case taking all the patient characteristics 
into account.
Discontinuation of the anti-VEGF treatment was dis-
cussed with the patient, in case BCVA was ,0.0625 decimals 
in the treated eye (when necessary, confirmed with below 
20 Early Treatment Diabetic Retinopathy Study (ETDRS) 
letters), or if the treatment was not expected to enhance the 
patient’s quality of life or ability to function.
In VA testing, when the largest optotype could not be 
recognized correctly, the classification was very low VA 
on a semiquantitative scale such as counting fingers (CF) 
and hand motion (HM). The very low VA measurements 
have been converted as follows: CF to 1.9 and HM to 2.3 
logarithm of minimum angle of resolution (logMAR) units.15 
For statistical purposes, the logMAR units for CF and HM 
were converted to the equivalent values of 0.013 and 0.005 
decimals, respectively.
TER protocol (anti-VEGF treatment 
protocol)
Anti-VEGF treatment was initiated with three loading doses 
of the primary drug bevacizumab given approximately 
4 weeks apart. After adequate treatment response was 
achieved with either bevacizumab or the secondary drug 
aflibercept, the treatment interval was lengthened gradually 
by 2 weeks up to 12 weeks. When intraretinal or subretinal 
fluid remained unchanged compared to the previous OCT 
scan, the treatment interval was maintained.
The treatment interval was shortened 2 weeks at a time 
if the examination showed any signs of recurrence, eg, when 
observing 1) any increase of intraretinal or subretinal fluid 
compared with the previous OCT scan, or 2) any increase in 
the size of pigment epithelial detachment compared with the 
previous OCT scan, or 3) any sign of exudation or new macu-
lar hemorrhage in slit-lamp biomicroscopic examination, or 4) 
worsening of subjective vision and BCVA in cases ambiguous 
by OCT. In case of a large recurrence of intra- or subretinal 
fluid associated with visual loss over 0.2 decimals, subfoveal 
or large extrafoveal hemorrhage, the treatment was reverted 
to monthly injections and then extended according to the 
treatment protocol. If a second recurrence was observed, the 
patient-specific maximum final interval was set at 2 weeks less 
than the period when the previous recurrence was observed.
The treatment intervals were recorded on every visit.
statistical analysis
Data are given as mean±standard error of the mean (SEM) and 
range (min–max) except for the absolute number and proportion 
for nominal scale. IBM SPSS Statistics 23 (SPSS Inc., Somers, 
NY, USA) was used for statistical analyses. A linear regression 
model was used to estimate the relationships between variables. 
P#0.05 was considered statistically significant.
Table 1 Baseline variables of 41 eyes with waMD of 37 patients 
not responding to bevacizumab
Nonresponders
Male:female (n/%) 12:25 (32:68)
age (years) 81.0±5.4 (70–93)
laterality (uni:bilateral) 22:15a (59:41)
Phakic:pseudophakic (n/%) 14:27 (34:66)
BCVA (decimal units) 0.29±0.14 (0.05–0.60)
CrT mean (µm) 459.7±157.6 (220–892)
CrT max (µm) 557.9±174.5 (299–1,098)
Notes: Baseline variables regarding patient and ophthalmic parameters. Data are 
given as mean (±sD) and range or absolute number and proportion. aOf 15 bilateral 
wAMD patients, 4 were bevacizumab nonresponders for both eyes; in the rest 
11 bilateral wAMD, the contralateral eye was treated with bevacizumab.
Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; 
wAMD, wet age-related macular degeneration.
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Results
Baseline patient and ophthalmic 
characteristics
The gender distribution was 12 males (32%) and 25 females 
(68%). The mean age at the time of initiation of primary intra-
vitreal treatment was 81 years (range 70–93 years). Of the 
37 study patients, 22 (59%) had unilateral and 15 (41%) had 
bilateral disease. Of those 15 study patients with bilateral 
disease, 4 (27%) were bevacizumab nonresponders for both 
eyes (Table 1).
Of the 41 study eyes, 14 (34%) were phakic and 27 (66%) 
were pseudophakic prior to initiation of the primary intra-
vitreal treatment. The baseline mean BCVA was 0.29 deci-
mals (range 0.05–0.60 decimals), CRT mean was 460 µm 
(range 220–892 µm), and CRT max was 558 µm (range 
299–1,098 µm; Table 1).
CrT change after the conversion to 
aflibercept in bevacizumab nonresponder 
eyes in short and long terms
The mean CRT at baseline was 459.7±157.6 µm (range 
220–892 µm). The corresponding values after bevacizumab 
loading phase with three injections and at the switch to 
aflibercept were 359.0±102.0 µm (range 213–654 µm) and 
361.1±117.7 µm (range 206–654 µm, respectively; Table 2).
The mean CRT after three aflibercept injections was 
301.3±88.7 µm (163–544 µm). At the study termination, a 
minimum of 1 year after the conversion to aflibercept, the 
mean CRT was 299.9±74.9 µm (range 164–483 µm; Table 2).
CRT change and final aflibercept treatment interval 
according to macular anatomical characteristics at the time 
of the switch to aflibercept are presented in Table 3.
BCVA gain after the conversion to 
aflibercept in bevacizumab nonresponder 
eyes in short and long terms
BCVA was 0.29±0.14 decimals (range 0.05–0.60 decimals) 
at baseline. The corresponding values after bevacizumab 
loading phase with three injections and at the switch to 
aflibercept were 0.30±0.19 (range 0.05–0.80) and 0.29±0.19 
(range 0.05–0.80) decimals, respectively (Table 4).
BCVA after three aflibercept injections was 0.36±0.24 
decimals (range CF–1.00 decimals). At the study termination, 
at least 1 year after the conversion to aflibercept, BCVA was 
0.33±0.23 decimals (range HM–0.80 decimals; Table 4).
The conversion to aflibercept results in 
visual acuity improvement for most eyes 
in short term but not in long term
Next, we analyzed the proportion of eyes responding to 
aflibercept switch regarding VA and macular anatomy.
Compared to the clinical status before the switch to 
aflibercept, anatomical response was found in 34 of the 
41 eyes (83%) after three aflibercept injections. At the study 
termination, anatomical response to aflibercept was main-
tained in 32 of the 41 eyes (78%).
After three aflibercept injections, BCVA improved in 
26 (63%), remained unchanged in 9 (22%), and declined in 
6 of the 41 eyes (15%) compared with the BCVA before the 
conversion to aflibercept (Table 5).
At the study termination, an improved BCVA was main-
tained in 17 of 41 eyes (41%). Eleven of the 41 eyes (27%) 
remained unchanged and 13 eyes (32%) had a declined 
BCVA compared with the BCVA before the switch to 
aflibercept (Table 5).
Irrespective of the fact that a dry macula was maintained 
with aflibercept injections in most of the patients, the distribu-
tion between eyes with improved, unchanged, or decreased 
BCVA was fairly even at the study end point. The change 
in CRT from aflibercept switch to that after the aflibercept 
loading phase (R2=0.028; P=0.299), and from aflibercept 
switch to study end point (R2=0.021; P=0.367) did not cor-
relate with the change in BCVA at given time points.
Finally, we analyzed the treatment intervals at the study 
end point. Six of the 41 study eyes (15%) were still in the 
extend phase of the TER protocol at the time point of the 
Table 2 CRT of 41 eyes with wet age-related macular degeneration not responding to bevacizumab
Mean Max
CrT at baseline 459.7±157.6 (220–892) 557.9±174.5 (299–1,098)
CRT after three bevacizumab injections 359.0±102.0 (213–654) 435.9±117.0 (265–725)
CRT at switch to aflibercept 361.1±117.7 (206–654) 459.1±126.6 (265–725)
CRT after three aflibercept injections 301.3±88.7 (163–544) 387.1±100.2 (256–638)
CRT final 299.9±74.9 (164–483) 393.8±96.9 (260–643)
Note: Data are given as mean (±sD) and range.
Abbreviation: CrT, central retinal thickness.
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analysis. The mean treatment interval with aflibercept was 
8.0±2.2 weeks (range 4–12 weeks; Table 6).
Discussion
Since the introduction of aflibercept, it has become an 
alternative treatment option for eyes with wAMD resistant 
to treatment with other anti-VEGF agents. In eyes with 
treatment-resistant wAMD, the conversion to aflibercept 
may result in a positive functional and anatomical response. 
A recent meta-analysis demonstrated that the switch to 
aflibercept results in a significant improvement in CRT, but 
the effect on VA is far more modest.11
In this study, we found that treatment with aflibercept in 
accordance with the TER protocol improves the anatomy and 
decreases CRT in most of the eyes with persistent macular 
fluid despite previous treatment with bevacizumab. A posi-
tive anatomical response was found in 83% of the eyes after 
three aflibercept injections and in 78% of the eyes at the end 
of the study. The positive anatomical results are consistent 
with other studies evaluating the effect of aflibercept on 
eyes resistant to previous treatment with other anti-VEGF 
agents.16–18 Compared with other anti-VEGF agents, afliber-
cept additionally binds PlGF and has a greater binding affinity 
to VEGF.9 Moreover, repeated injections with bevacizumab 
or ranibizumab can lead to immunoreactivity against mouse-
derived humanized monoclonal antibodies and/or tachyphy-
laxis with loss of therapeutic effect,19–21 and switching to 
another anti-VEGF agent can overcome this issue.22
Irrespective of the fact that a dry macula was maintained 
with aflibercept injections throughout the study in most of the 
patients, the positive anatomical results did not correlate with 
restoration of visual function. The proportion of eyes with an 
improved, unchanged, or decreased BCVA was distributed 
fairly evenly at the end of the study. Compared with our 
data, some previous studies have reported a more significant 
functional response,16,17 and on the contrary, one study demon-
strated a decrease in mean BCVA after a 2-year follow-up.18 
Aflibercept is considerably more expensive than bevacizumab, 
which makes a question regarding the cost-effectiveness of 
the conversion to aflibercept. Of note, aflibercept switch may 
improve contrast sensitivity and thus vision-related quality of 
life,23 even without changes in BCVA.24
Table 3 Anatomical and treatment response according to macular status at switch to aflibercept
Macular status at switch 
to aflibercept
CRT change after three 
aflibercept injections (μm)
CRT change final (μm) Treatment interval 
final (weeks)
IRF
no (n=6) (15%) 5.0±37.9 -17.7±25.3 10.0±2.2
Yes (n=35) (85%) -71.0±80.6 -68.7±109.4 7.6±2.0
PED
no (n=17) (41%) -30.2±50.2 -32.9±81.7 8.5±2.1
Yes (n=24) (59%) -80.9±91.3 -81.3±112.9 7.6±2.3
Subretinal fluid
no (n=19) (46%) -46.4±68.2 -46.2±99.7 7.9±2.3
Yes (n=22) (54%) -71.4±89.2 -74.2±106.0 8.0±2.2
Subretinal fibrosis
no (n=39) (95%) -53.9±69.5 -54.8±93.8 8.0±2.3
Yes (n=2) (5%) -176.0±213.5 -187.5±235.5 8.0±0.0
Note: Data are given as absolute numbers and proportions or mean (±sD).
Abbreviations: CRT, central retinal thickness; IRF, intraretinal fluid; PED, pigment epithelial detachment.
Table 4 Visual acuity of 41 eyes with wet age-related macular 
degeneration not responding to bevacizumab
BCVA
at baseline 0.29±0.14 (0.05–0.60)
After three bevacizumab injections 0.30±0.19 (0.05–0.80)
At switch to aflibercept 0.29±0.19 (0.05–0.80)
After three aflibercept injections 0.36±0.24 (CF–1.00)
at study end point 0.33±0.23 (hM–0.80)
Note: Data are given as mean (±sD) and range.
Abbreviations: BCVA, best-corrected visual acuity; CF, counting fingers; HM, 
hand motion.
Table 5 Visual acuity outcome after switch to aflibercept of 
41 wAMD eyes not responding to bevacizumab
After three 
aflibercept injections
At study 
end point
BCVA gain (N=eyes) 26 (63%) 17 (41%)
BCVA unchanged (N=eyes) 9 (22%) 11 (27%)
BCVA decline (N=eyes) 6 (15%) 13 (32%)
Notes: Data are given as the absolute number and proportion. The follow-up was 
at least 1 year from the switch to aflibercept.
Abbreviations: BCVA, best-corrected visual acuity; wAMD, wet age-related 
macular degeneration.
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It can be reasoned that the lack of significant functional 
response in long term might be related to progression of 
retinal atrophic changes. VEGF has an essential role in 
maintaining the cone photoreceptors and choroid vasculature, 
and it has been suggested that persistent VEGF antagonism 
in the eye might have detrimental side-effects.25 Anti-VEGF 
treatment has been associated with accelerated progression 
and development of geographic atrophy.26–28 One could argue 
that the functional unresponsiveness might be a result of 
permanent damage of the macula before the conversion to 
aflibercept. In that case, a minimal delay in the conversion 
of the treatment-resistant eyes to aflibercept could lead to 
better functional results.
This study has several limitations. First, the patients’ 
baseline characteristics are heterogeneous regarding the 
severity of the disease and the duration of the previous 
treatment with bevacizumab. The decision of the treatment 
modality was nonrandomized and at the discretion of the 
treating clinician. This reflects the real-life setting of the 
study. The lack of a control group also makes the interpreta-
tion of the results more difficult. The strength of the study 
was its long follow-up to evaluate the effects of the switch 
to aflibercept also in the long run. The growing real-world 
evidence of the aflibercept switch on the anatomical, func-
tional, and quality of life outcomes helps physicians to weigh 
the pros and cons of the switch for the individual.
In conclusion, this study added real-world evidence that 
most of the eyes resistant to treatment with bevacizumab 
expressed a positive anatomical response. In addition, treat-
ment interval was doubled following the switch to aflibercept 
using the TER protocol. However, with poor correlation 
between the anatomical results and the BCVA improvement, 
further studies concentrating on other visual function param-
eters and quality of life outcomes are warranted.
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